DelveInsight's 'Primary Myelofibrosis Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline primary myelofibrosis therapies in various stages of ...

Please provide your email address to receive an email when new articles are posted on . Study results presented at Society of Hematologic Oncology Annual Meeting highlight the potential effect that ...

Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Primary Myelofibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...

Review of criteria used to assess and plan treatment for a 67-year-old patient with primary myelofibrosis. John Mascarenhas, MD: Let’s move on to the first patient case. This is a 67-year-old woman ...

Moshe Talpaz, MD: Let’s discuss a little bit of myelofibrosis. Myelofibrosis is a relatively uncommon disease that is part of a group of conditions known as myeloproliferative neoplasia. Those are ...

Moving on to review the first patient scenario of primary myelofibrosis, panelists elucidate the decisionmaking process when selecting JAK inhibitor therapy. This patient highlights one of the ...

The findings, coming from nearly a decade’s worth of retrospective data on patients aged at least 65 years, offer real-world evidence on the treatment’s impact on survival. Ruxolitinib (Rx) treatment ...

A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 ...

The inclusion of cytogenetic and mutation information boosted the predictive power of a popular risk scoring system for primary myelofibrosis. In a recent Mayo Clinic study, roughly 1 in 4 patients in ...

Primary myelofibrosis (PMF), a relatively rare but painful type of bone marrow cancer, disrupts the body's normal production of blood cells by causing extensive scarring in the bone marrow. Today, the ...